

C.V.

Full Name: Yong-Sung Kim

Organization: Dept. of Molecular Science and Technology, Ajou University

Position & Title: Professor, Director, BK21 four program of Chem-Bio Medicine, Graduate School

Educational background & professional experience (in sequence of the latest year)

2020.09 ~ present: Director, BK21 four program of Chem-Bio Medicine, Graduate School

2020.01 ~ 2021.12: President, Antibody Society Korea (ASK)

2010.09 ~ 2011.08: Visiting Scholar (Sabbatical) at Genentech Inc. (San Francisco, USA)

2002.11 ~ 2004.02: Postdoctoral Associate at Division of Biological Engineering, Massachusetts Institute of Technology (MIT)

1999.03 ~ 2002.12: Ph.D., The University of Colorado, Denver, USA

Department of Pharmaceutical Sciences and Center for Pharmaceutical Biotechnology

1996.03 ~ 1998.02: M.Sc., Korea Advanced Institute of Sciences and Technology, Korea

Department of Biological Sciences

1990.03 ~ 1996.02: B.Sc., Seoul National University, Korea

Research Interests

Development of next generation antibody platform technology

Bispecific antibody development

Development of cell/tissue-specific cell-penetrating antibody

Cancer Immunotherapy

Publications (as a corresponding author)

Shin SM et al. Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth. **Science Advances**, 2020 January, 6(3):eaay2174.

Jung K et al. A neuropilin-1 antagonist exerts anti-tumor immunity by inhibiting the suppressive function of intratumoral regulatory T cells. **Cancer Immunology Research**. 2020 January 109(1):104-115.

Kim YJ et al. Dual-targeting of EGFR and Neuropilin-1 Attenuates Resistance to EGFR-targeted Antibody Therapy in KRAS-mutant Non-Small Cell Lung Cancer. **Cancer Letters**. 2019 December 1, 466:23-34.

Jung K et al. Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells. **Oncoimmunology**. 7:7, e1438800.

Shin SM et al. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. **Nature Communications** 8:15090 (2017)

Kim YJ et al. Co-targeting of EGF Receptor and Neuropilin-1 Overcomes Cetuximab Resistance in Pancreatic Ductal Adenocarcinoma with Integrin β 1-driven Src-Akt Bypass Signaling. **Oncogene**. May 4, 36(18):2543-2552. ISSN: 0950-9232.